Founded by scientists out of Yale University working with other scientists in dermatology, microbiology, and genetic engineering, Azitra is organized around advancing its programs in atopic dermatitis and targeted orphan indications. The focus is on bringing microbiome-based therapeutics to the treatment of skin diseases. Azitras proprietary candidate, "AZT-01," is a recombinant strain of a safe, commensal skin bacterium that secretes therapeutic proteins for the treatment of skin disease. At the intersection of the fields of microbiomics, synthetic biology, and protein engineering Azitra is developing a microbiome based platform to deliver innovative, inexpensive, and sustainable treatments for skin disease and conditions ranging from atopic dermatitis to MRSA skin infections using our novel bacterial platform engineered to secrete therapeutic proteins.
